Trial Profile
Prospective Randomized Trial of an Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma (MCC) With Immune Checkpoint Blocking Antibodies (Nivolumab, Opdivo; Ipilimumab (Yervoy) Every 3 Weeks for 12 Weeks Versus Observation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- Acronyms ADMEC; ADMEC- O; DeCOG/ADO study
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Planned End Date changed from 31 Aug 2022 to 31 Aug 2024.
- 13 Sep 2022 Planned primary completion date changed from 31 Aug 2022 to 31 Aug 2024.